查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423650

到 2030 年停经后骨质疏鬆症治疗市场预测：按治疗类型、给药途径、给药系统、患者人口统计、分销管道和地区进行全球分析

Postmenopausal Osteoporosis Treatment Market Forecasts to 2030 - Global Analysis By Treatment Type, By Route of Administrations, By Drug Delivery System, Patient Demographics, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球停经后骨质疏鬆症治疗市场规模将达到 81 亿美元，预计 2030 年将达到 126 亿美元，预测期内复合年增长率为 6.6%。

停经后骨质疏鬆症治疗包括药物治疗和生活方式改变，以减轻停经后妇女的骨质流失。常见的治疗方法包括双磷酸盐、荷尔蒙疗法和单株抗体，旨在增强骨骼并降低骨折风险。这些治疗方法可以帮助维持骨骼密度、缓解症状并改善整体骨骼健康。

根据世界卫生组织（WHO）2021年10月的报告，60岁及以上的人口预计将从2020年的10亿增加到2030年的14亿和2050年的21亿。我是。根据国际更年期协会（IMS）公布的资料，预计2021年将有超过2亿女性受到骨质疏鬆症的影响，其中三分之一的50岁以上女性会因骨质疏鬆症而发生骨折。 。

世界老化人口增加

随着越来越多的人在闭经后患有骨质疏鬆症，骨质疏鬆症（一种以骨骼密度下降和骨折风险增加为特征的疾病）的盛行率也在增加。这些人口变化正在增加对有效治疗方案的需求，并推动研究和开发工作，以满足停经后妇女的独特需求。製药公司越来越注重治疗方法，以帮助解决老龄化人口对骨质疏鬆症相关併发症的脆弱性。随着医疗保健系统努力满足不断变化的需求，它正在推动市场成长。

治疗费用高

与骨质疏鬆症药物和治疗方法相关的经济负担对广泛提供和负担得起的治疗提出了挑战，特别是对于医疗资源有限和保险不足地区的患者而言。我是。骨质疏鬆症的治疗费用通常不仅包括药物费用，还包括诊断程序、监测测试和潜在副作用的管理，进一步加重了患者的经济负担。由于骨质疏鬆症是一种需要长期管理的慢性疾病，累积的财务影响可能会阻碍人们寻求和继续治疗。

人们越来越认识到骨骼健康的重要性

人们对骨质疏鬆症风险和后果的认识不断提高，增加了对预防和治疗性介入的需求。公共教育宣传活动和倡议在鼓励个人优先考虑骨骼健康、及时检查和接受适当治疗方面发挥着至关重要的作用。这种认知的提升不仅有助于早期诊断，还能鼓励骨质疏鬆症药物的采用，鼓励患者更好地照顾自己的骨骼健康，预防停经后骨质疏鬆症相关的併发症，创造积极的市场环境。

副作用和安全问题

虽然各种药物干预措施旨在解决停经后妇女的骨骼健康问题，但潜在的副作用可能导致患者依从性降低和治疗停止。胃肠道紊乱、肌肉骨骼疼痛等常见副作用，以及某些情况下非典型骨折和下颚骨坏死等严重併发症，引起了患者和医疗保健提供者的担忧。这些安全问题不仅影响受影响人群的生活质量，也损害了市场的信誉和可信度。

COVID-19 的影响：

COVID-19 的疫情对市场产生了重大影响。封锁、医疗服务中断以及对抗病毒的资源转移给患者诊断和治疗带来了挑战。医疗预约的延误和患者就诊的减少正在影响骨质疏鬆症的管理。此外，供应链中断也影响了药品的供应。然而，大流行加速了远端医疗和数位医疗解决方案的采用，为患者照护提供了替代方案。对整体医疗保健弹性和预防措施重要性的关注可能会影响停经后骨质疏鬆症管理的疫情后策略。

荷尔蒙替代疗法预计将成为预测期内最大的市场

荷尔蒙替代疗法领域预计将出现良好的成长。在停经后女性中，雌激素水平下降会增加骨吸收并增加骨质疏鬆症的风险。荷尔蒙替代疗法透过施用雌激素（有时还施用黄体素）来帮助维持骨骼密度并防止骨折，从而减少这些影响。儘管已证明有效，但由于相关风险（包括心血管问题），荷尔蒙替代疗法的使用仍需经过仔细评估。正在进行的研究重点是优化 HRT通讯协定，以最大限度地提高疗效，同时最大限度地减少停经后骨质疏鬆症管理的潜在缺点。

预计医院药房行业在预测期内的复合年增长率最高。

预计医院药房业务在预测期内将以最快的复合年增长率成长。医院药房确保处方药物的供应，提供病患教育，并促进医疗保健专业人员和接受停经后骨质疏鬆症治疗的患者之间的无缝合作。医院药房透过药物管理方面的专业知识促进治疗医嘱遵从性，并为患者提供获取所需药物（包括新兴和创新治疗方法）的中心枢纽。这种重要作用凸显了其在支持有效的医疗保健提供和促进停经后骨质疏鬆症治疗取得良好结果方面的重要性。

比最大的地区

预计北美市场在预测期内将继续占据大部分市场。该地区停经后骨质疏鬆症盛行率很高，对有效治疗方法的需求很高。技术进步、知名製药公司和有利的报销政策正在促进市场成长。此外，该地区正在进行的研究计划和临床试验重点关注创新治疗方法，将北美定位为停经后骨质疏鬆症新先进治疗方法开发和商业化的领先中心。

复合年增长率最高的地区：

在健康意识不断提高的推动下，预计亚太地区在预测期内将呈现最高的复合年增长率。人口老化和骨质疏鬆症的高盛行率，特别是在日本和中国等国家，增加了对有效治疗方法的需求。医疗保健意识的提高、医疗设施的改善以及政府解决女性健康问题的倡议正在进一步推动市场扩张。此外，製药公司和医疗机构之间的合作，加上治疗方法的进步，正在推动技术创新，改善亚太地区停经后骨质疏鬆症治疗的整体格局。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球停经后骨质疏鬆症治疗市场：依治疗类型

  • 双磷酸盐
  • 荷尔蒙替代疗法（HRT）
  • 选择性雌激素受体调节剂 (SERM)
  • 单株抗体
  • 钙和维生素 D补充品
  • 合成代谢剂
  • 其他治疗类型

第六章全球停经后骨质疏鬆症治疗市场：依给药途径

  • 口服
  • 胃肠外的
    • 静脉注射(IV)
    • 肌肉注射
    • 皮下的
  • 经皮的
  • 鼻腔

第七章全球停经后骨质疏鬆症治疗市场：依给药系统分类

  • 常规配方
  • 长效製剂

第八章全球停经后骨质疏鬆症治疗市场：病患分层

  • 停经后妇女
  • 老年人口

第九章全球停经后骨质疏鬆症治疗市场：按分销管道

  • 医院药房
  • 零售药房
  • 网路药房

第十章全球停经后骨质疏鬆症治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • AbbVie Company（Allergan Pharmaceuticals International Ltd.）
  • Sun Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • BiologicsMD
  • Chugai Pharma China Co., Ltd.（Roche）
  • Clonz Biotech
  • Proctor & Gamble Co.
  • Eli Lilly and Company
  • Enteris BioPharma
  • Ligand Pharmaceuticals Incorporated.
  • Pfizer Inc.
  • Merck Sharp & Dohme Corp.（Merck & Co., Inc.）
  • Mylan Inc.（Viatris）
  • Oncobiologics, Inc.
  • Novartis International AG
Product Code: SMRC24884

According to Stratistics MRC, the Global Postmenopausal Osteoporosis Treatment Market is accounted for $8.1 billion in 2023 and is expected to reach $12.6 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Postmenopausal osteoporosis treatment involves medications and lifestyle modifications to mitigate bone loss in women after menopause. Common treatments include bisphosphonates, hormone therapy, and monoclonal antibodies, which aim to strengthen bones and reduce fracture risk. These treatments help maintain bone density, alleviate symptoms and enhance overall bone health.

According to the World Health Organization's October 2021 report, the population of people of age 60 years and more is expected to increase from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. According to data published by the International Menopause Society (IMS), in 2021, more than 200 million women are estimated to suffer from osteoporosis, and 1 in 3 women aged more than 50 is expected to experience osteoporosis fracture.

Market Dynamics:

Driver:

The increasing global aging population

With a rising number of individuals entering the postmenopausal phase, there is a subsequent increase in the prevalence of osteoporosis, a condition characterized by reduced bone density and increased fracture risk. This demographic shift creates a growing demand for effective treatment options to address the specific needs of postmenopausal women, fostering research and development initiatives. Pharmaceutical companies are increasingly focusing on developing therapies tailored to this demographic, ranging from innovative drugs to targeted interventions, driving market growth as healthcare systems strive to meet the evolving needs of an aging population susceptible to osteoporosis-related complications.

Restraint:

High treatment costs

The financial burden associated with osteoporosis medications and therapies poses challenges to widespread accessibility and affordability, particularly for patients in regions with limited healthcare resources or inadequate insurance coverage. The cost of osteoporosis treatment often includes not only medication expenses but also diagnostic procedures, monitoring tests, and potential side-effect management, further exacerbating the economic burden on patients. As osteoporosis is a chronic condition requiring long-term management, the cumulative financial impact can dissuade individuals from seeking or continuing treatment.

Opportunity:

Growing awareness regarding the importance of bone health

As awareness grows regarding the risks and consequences of osteoporosis, there is a heightened demand for preventive and therapeutic interventions. Public education campaigns and healthcare initiatives play a pivotal role in encouraging individuals to prioritize bone health, undergo timely screenings, and seek appropriate treatment. This heightened awareness not only fosters early diagnosis but also propels the adoption of osteoporosis treatments, creating a positive market environment where patients are more proactive in managing their bone health and preventing complications associated with postmenopausal osteoporosis.

Threat:

Adverse effects and safety issues

While various pharmaceutical interventions aim to address bone health in postmenopausal women, the potential for adverse reactions may lead to decreased patient compliance and treatment discontinuation. Common side effects such as gastrointestinal disturbances, musculoskeletal pain, and, in some cases, severe complications like atypical fractures or osteonecrosis of the jaw raise concerns among both patients and healthcare providers. These safety issues not only impact the quality of life for affected individuals but also undermine the market's credibility and trust.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the market. Lockdowns, disrupted healthcare services, and diverted resources to combat the virus have led to challenges in patient diagnosis and treatment accessibility. Delayed medical appointments and reduced patient visits have affected osteoporosis management. Additionally, supply chain disruptions have impacted drug availability. However, the pandemic has accelerated the adoption of telemedicine and digital health solutions, offering alternative avenues for patient care. The focus on overall healthcare resilience and the importance of preventive measures may influence post-pandemic strategies in managing postmenopausal osteoporosis.

The hormone replacement therapy is expected to be the largest during the forecast period

The hormone replacement therapy segment is expected to have a lucrative growth. In postmenopausal women, reduced estrogen levels result in increased bone resorption, elevating the risk of osteoporosis. HRT involves the administration of estrogen and sometimes progestin to mitigate these effects, promoting bone density maintenance and fracture prevention. Despite proven efficacy, HRT usage is carefully evaluated due to associated risks, such as cardiovascular concerns. Ongoing research focuses on optimizing HRT protocols to maximize benefits while minimizing potential drawbacks in postmenopausal osteoporosis management.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is anticipated to witness the fastest CAGR growth during the forecast period. They ensure the availability of prescribed treatments, provide patient education, and facilitate seamless coordination between healthcare professionals and individuals undergoing postmenopausal osteoporosis treatment. Hospital pharmacies contribute to treatment adherence through their expertise in medication management, offering a centralized hub for patients to obtain necessary medications, including emerging and innovative therapies. This integral role underscores their significance in supporting effective healthcare delivery and promoting positive outcomes in the management of postmenopausal osteoporosis.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market driven by a substantial aging population and advanced healthcare infrastructure. The region benefits from a high prevalence of postmenopausal osteoporosis, necessitating a robust demand for effective treatments. Technological advancements, well-established pharmaceutical companies, and favorable reimbursement policies contribute to the market's growth. Moreover, ongoing research initiatives and clinical trials in the region focus on innovative therapies, positioning North America as a key hub for the development and commercialization of new and advanced treatments for postmenopausal osteoporosis.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, driven by a growing health-conscious population. The increasing aging population, particularly in countries like Japan and China, contributes to a higher prevalence of osteoporosis, driving the demand for effective treatments. Rising healthcare awareness, improving access to medical facilities, and government initiatives to address women's health issues further propel market expansion. Additionally, collaborations between pharmaceutical companies and healthcare organizations, coupled with advancements in treatment options, are fostering innovation and enhancing the overall landscape for postmenopausal osteoporosis treatment in the Asia Pacific region.

Key players in the market

Some of the key players in Postmenopausal Osteoporosis Treatment market include AbbVie Company (Allergan Pharmaceuticals International Ltd.), Sun Pharmaceutical Industries Ltd., Amgen Inc., BiologicsMD, Chugai Pharma China Co., Ltd. (Roche), Clonz Biotech, Proctor & Gamble Co., Eli Lilly and Company, Enteris BioPharma, Ligand Pharmaceuticals Incorporated., Pfizer Inc., Merck Sharp & Dohme Corp. (Merck & Co., Inc.), Mylan Inc. (Viatris), Oncobiologics, Inc. and Novartis International AG.

Key Developments:

In February 2023, Sandoz received Biologics License Application (BLA) from US Food and Drug Administration (FDA) for a prospective biosimilar of denosumab (Prolia and Xgeva; Amgen). The product is intended for addressing a wide range of conditions, such as osteoporosis in postmenopausal women and in men with an elevated fracture risk, alongside numerous other medical conditions.

In July 2022, Chugai Pharma China Co., Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd. launched Edirol (eldecalcitol) in China after receiving approval from the China National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis. Edirol is an active vitamin D3 derivative created by Chugai.

Treatment Types Covered:

  • Bisphosphonates
  • Hormone Replacement Therapy (HRT)
  • Selective Estrogen Receptor Modulators (SERMs)
  • Monoclonal Antibodies
  • Calcium and Vitamin D Supplements
  • Anabolic Agents
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Transdermal
  • Nasal

Drug Delivery Systems Covered:

  • Conventional Formulations
  • Long-Acting Formulations

Patient Demographics Covered:

  • Postmenopausal Women
  • Elderly Population

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Postmenopausal Osteoporosis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Bisphosphonates
  • 5.3 Hormone Replacement Therapy (HRT)
  • 5.4 Selective Estrogen Receptor Modulators (SERMs)
  • 5.5 Monoclonal Antibodies
  • 5.6 Calcium and Vitamin D Supplements
  • 5.7 Anabolic Agents
  • 5.8 Other Treatment Types

6 Global Postmenopausal Osteoporosis Treatment Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Parenteral
    • 6.3.1 Intravenous (IV)
    • 6.3.2 Intramuscular
    • 6.3.3 Subcutaneous
  • 6.4 Transdermal
  • 6.5 Nasal

7 Global Postmenopausal Osteoporosis Treatment Market, By Drug Delivery System

  • 7.1 Introduction
  • 7.2 Conventional Formulations
  • 7.3 Long-Acting Formulations

8 Global Postmenopausal Osteoporosis Treatment Market, By Patient Demographics

  • 8.1 Introduction
  • 8.2 Postmenopausal Women
  • 8.3 Elderly Population

9 Global Postmenopausal Osteoporosis Treatment Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Postmenopausal Osteoporosis Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Company (Allergan Pharmaceuticals International Ltd.)
  • 12.2 Sun Pharmaceutical Industries Ltd.
  • 12.3 Amgen Inc.
  • 12.4 BiologicsMD
  • 12.5 Chugai Pharma China Co., Ltd. (Roche)
  • 12.6 Clonz Biotech
  • 12.7 Proctor & Gamble Co.
  • 12.8 Eli Lilly and Company
  • 12.9 Enteris BioPharma
  • 12.10 Ligand Pharmaceuticals Incorporated.
  • 12.11 Pfizer Inc.
  • 12.12 Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
  • 12.13 Mylan Inc. (Viatris)
  • 12.14 Oncobiologics, Inc.
  • 12.15 Novartis International AG

List of Tables

  • Table 1 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 3 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Bisphosphonates (2021-2030) ($MN)
  • Table 4 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hormone Replacement Therapy (HRT) (2021-2030) ($MN)
  • Table 5 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2021-2030) ($MN)
  • Table 6 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 7 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Calcium and Vitamin D Supplements (2021-2030) ($MN)
  • Table 8 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Anabolic Agents (2021-2030) ($MN)
  • Table 9 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 10 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 11 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 12 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 13 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intravenous (IV) (2021-2030) ($MN)
  • Table 14 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 15 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 16 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Transdermal (2021-2030) ($MN)
  • Table 17 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Nasal (2021-2030) ($MN)
  • Table 18 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Drug Delivery System (2021-2030) ($MN)
  • Table 19 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Conventional Formulations (2021-2030) ($MN)
  • Table 20 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Long-Acting Formulations (2021-2030) ($MN)
  • Table 21 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Patient Demographics (2021-2030) ($MN)
  • Table 22 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Postmenopausal Women (2021-2030) ($MN)
  • Table 23 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Elderly Population (2021-2030) ($MN)
  • Table 24 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 25 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 26 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 27 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.